Two Phase 3 trials have found that tirzepatide, a medication used to treat type 2 diabetes, reduced apnea events and body weight in patients with obstructive sleep apnea and obesity. Tirzepatide had comparable safety results to placebo in the two trials.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: